Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in Episodic Migraine Prevention: A Multicentric Observational Study
Objective: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop) in the prophylactic treatment of episodic migraine without aura (MO). Methods: Eighty patients suffering from MO for at least 6 months with a monthly frequency of 3 to 8 attacks and 4 to12 headache days, were enrolled in this open study and treated with Aurastop twice daily per os for 3 months. The reduction of headache days per month was assessed as the primary end-point, while the secondary end-points were: 1) reduction of the number of MO attacks; 2) reduction of intensity of the pain; 3) reduction of acute treatment drug intake; 4) subjective change of pain intensity. Results: All the parameters significantly improved at the end of the observational period of treatment with Aurastop. In more detail: a significant reduction of the number of headache days (from 9.1 ± 2.0 before treatment to 3.2 ± 1.8 post treatment, p < 0.001); number of attacks per month (from 6.0 ± 1.2 to 2.4 ± 1.1, p < 0.001); pain intensity (in a visual analogical scale [VAS]: from 7 ± 1.0 to 3.2 ± 0.7, p < 0.001); number of drug doses for acute treatment (triptans, simple analgesics or in combination) assumed by each subject per month (from 9.5 ± 1.8 to 2.2 ± 1.1, p < 0.001). No serious adverse events were observed. Conclusion: Albeit obtained with the limitation of open-trials, our findings suggest that AURASTOP is a promising approach for migraine prevention; further investigations are required to confirm the safety and efficacy of this treatment.
Cite this paper
Mainardi, F. , Merlo, P. , Maggioni, F. , Zanchin, G. and Volta, G. D. (2018). Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in Episodic Migraine Prevention: A Multicentric Observational Study. Open Access Library Journal, 5, e4765. doi: http://dx.doi.org/10.4236/oalib.1104765.
GBD 2015 Neurological Disorder Collaborator Group (2017) Global, Regional and National Burden of Neurological Disorders during 1990-2015; A Systematic Analysis for the Global Burden of Disease Study 2015. Lancet Neurology, 16, 877-897.
Lipton, R.B., Bigal, M.E., Diamond, M., et al. (2007) Migraine Prevalence, Disease Burden, and the Need for Preventive Therapy. Neurology, 68, 343-349. https://doi.org/10.1212/01.wnl.0000252808.97649.21
Bloudek, L.M., Stokes, M., Buse, D.C., Wilcox, T.K., Lipton, R.B., Goadsby, P.J., et al. (2012) Cost of Healthcare for Patients with Migraine in Five European Countries: Results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain, 13, 361-378. https://doi.org/10.1007/s10194-012-0460-7
Rajapakse, T. and Pringsheim, T. (2016) Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use. Headache, 56, 808-816. https://doi.org/10.1111/head.12789
Tassorelli, C., Greco, R., Morazzoni, P., Riva, A., Sandrini, G. and Nappi, G. (2005) Parthenolide Is the Component of Tanacetum parthenium That Inhibits Nitroglycerin-Induced Fos Activation: Studies in an Animal Model of Migraine. Cephalalgia, 25, 612-621. https://doi.org/10.1111/j.1468-2982.2005.00915.x
Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd Edition (Beta Version). Cephalalgia, 33, 629-808.
Materazzi, S., Benemei, S., Fusi, C., et al. (2013) Parthenolide Inhibits Nociception and Neurogenic Vasodilatation in the Trigeminovascular System by Targeting the TRPA1 Channel. Pain, 154, 2750-2758. https://doi.org/10.1016/j.pain.2013.08.002
Begon, S., Pickering, G., Eschalier, A., et al. (2001) Role of Spinal NMDA Receptors, Protein Kinase C and Nitric Oxide Synthase in the Hyperalgesia Induced by Magnesium Deficiency in Rats. British Journal of Pharmacology, 134, 1227-1236. https://doi.org/10.1038/sj.bjp.0704354
Sun-Edelstein, C. and Mauskop, A. (2009) Role of Magnesium in the Pathogenesis and Treatment of Migraine. Expert Review of Neurotherapeutics, 9, 369-379. https://doi.org/10.1586/14737175.9.3.369
Mody, I., Lambert, J.D. and Heinemann, U. (1987) Low Extracellular Magnesium Induces Epileptiform Activity and Spreading Depression in Rat Hippocampal Slices. Journal of Neurophysiology, 57, 869-888. https://doi.org/10.1152/jn.1987.57.3.869
Teigen, L. and Boes, C.J. (2015) An Evidence-Based Review of Oral Magnesium Supplementation in the Preventive Treatment of Migraine. Cephalalgia, 35, 912-922. https://doi.org/10.1177/0333102414564891
Chauvel, V., Vamos, E., Pardutz, A., et al. (2012) Effect of Systemic Kynurenine on Cortical Spreading Depression and Its Modulation by Sex Hormones in Rat. Experimental Neurology, 236, 207-214. https://doi.org/10.1016/j.expneurol.2012.05.002
Curto, M., Lionetto, L., Negro, A., et al. (2015) Altered Kynurenine Pathway Metabolites in Serum of Chronic Migraine Patients. Journal of Headache and Pain, 17, 47. https://doi.org/10.1186/s10194-016-0638-5
Merlo, P., Maggioni, F., Zanchin, G., et al. (2017) Efficacy in Episodic Migraine Prevention of a Combination of Tanacethum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop). A Multicentric Observational Study. Journal of Headache and Pain, 18, 202.
Zavarize, P., Pezzini, A. and Dalla Volta, G. (2017) Combination of Tanacethum partenium, 5-Hydrossitriptophan (5-Http) and Magnesium in the Prophylaxis of Episodic Migraine without Aura (AURASTOP) An Observational Study. International Journal of Neurology and Brain Disorders, 4, 1-4.
https://doi.org/10.15436/2377-1348.17.1630
